The GLP-1 receptor agonist reduces both calorie intake through appetite suppression and slightly increases energy expenditure, creating a caloric deficit that drives weight loss
[2] Novo Nordisk and Eli Lilly Globally, the GLP-1 medications market is controlled by two major pharmaceutical companies, U.S.-based Eli Lilly and Denmark-based Novo Nordisk
Patients who push through the first four to eight weeks of treatment, with appropriate management of their symptoms, typically find that side effects improve substantially even as the dose continues to increase
This proactive approach is supported by science and emphasizes the optimization of five key hormones to enhance weight control
I can't remember if she has celiac or not, but she can't absorb B12 or other nutrients I am sure
Reduces Oxidative Stress Free radicals from pollution, UV rays, and stress contribute to inflammation and skin damage